{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:42:17Z","timestamp":1793371337358,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background and Objectives: The triglyceride-to-high-density lipoprotein cholesterol ratio (TG\/HDL-C) is a simple lipid index associated with insulin resistance and atherogenic dyslipidemia. Previous evidence has supported the TG\/HDL-C ratio as a simple surrogate marker of insulin resistance and an adverse metabolic profile. However, its relationship with glycemic control in real-world patients with type 2 diabetes mellitus (T2DM) remains uncertain. This study evaluated the association between the TG\/HDL-C ratio and poor glycemic control in patients with T2DM. Materials and Methods: This retrospective observational study included patients with T2DM followed in outpatient clinics. Poor glycemic control was defined as glycated hemoglobin A1c (HbA1c) \u2265 7%. The association between the TG\/HDL-C ratio and glycemic control was assessed using group comparisons, Spearman correlation, tertile analysis, and multivariable logistic regression adjusted for age, sex, LDL-C, total cholesterol, insulin use, statin use, and fenofibrate use. Receiver operating characteristic (ROC) analysis was used to evaluate the discriminatory performance of the TG\/HDL-C ratio for identifying poor glycemic control. A sensitivity analysis was performed after excluding patients receiving fenofibrate. Results: A total of 1001 patients with T2DM were included, of whom 568 (56.7%) had poor glycemic control. The mean age was 60.9 \u00b1 11.4 years, and 57.1% of participants were women. The poor- and adequate-glycemic-control groups were comparable with respect to age and sex. The TG\/HDL-C ratio was higher in patients with HbA1c \u22657% than in those with HbA1c &lt; 7% [3.35 (2.35\u20135.00) vs. 2.74 (1.87\u20133.82), p &lt; 0.001] and increased progressively across tertiles. In multivariable analysis, the TG\/HDL-C ratio remained associated with poor glycemic control after adjustment for available covariates (OR: 1.201, 95% CI: 1.125\u20131.282, p &lt; 0.001). The association remained significant after excluding fenofibrate users. ROC analysis showed modest discrimination (AUC: 0.601, 95% CI: 0.566\u20130.636). Conclusions: The TG\/HDL-C ratio was associated with poor glycemic control in patients with T2DM, showing a graded association across tertiles. However, its standalone discriminatory performance is modest. Given its modest discriminatory performance, the TG\/HDL-C ratio should not be considered a standalone diagnostic or predictive tool for poor glycemic control; rather, it may serve as an accessible adjunctive metabolic marker associated with an adverse glycemic and lipid profile.<\/jats:p>","DOI":"10.3390\/biomedicines14091995","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:07:32Z","timestamp":1788538052000},"page":"1995","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association Between the Triglyceride-to-HDL Cholesterol Ratio and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Real-World Retrospective Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-4714","authenticated-orcid":false,"given":"Ali","family":"Erol","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Bursa Y\u00fcksek \u0130htisas Training and Research Hospital, 16100 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-4057","authenticated-orcid":false,"given":"Muhammet Fatih","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kestel State Hospital, 16100 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-8587(25)00299-2","article-title":"11th edition of the IDF Diabetes Atlas: Global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi","year":"2026","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lamprou, S., Koletsos, N., Zografou, I., Lazaridis, A., Mintziori, G., Trakatelli, C.M., Kotsis, V., Gkaliagkousi, E., Doumas, M., and Triantafyllou, A. (2024). Skin microvascular dysfunction in type 2 diabetes mellitus using laser speckle contrast analysis and association with carotid intima-media thickness. J. Clin. Med., 13.","DOI":"10.3390\/jcm13164957"},{"key":"ref_5","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026). Cardiovascular disease and risk management: Standards of care in diabetes\u20142026. Diabetes Care, 49, S216\u2013S245."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: Where are we?","volume":"58","year":"2015","journal-title":"Diabetologia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Diabetic dyslipidaemia: From basic research to clinical practice","volume":"46","author":"Taskinen","year":"2003","journal-title":"Diabetologia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncpendmet1066","article-title":"Dyslipidemia in type 2 diabetes mellitus","volume":"5","author":"Mooradian","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5551\/jat.RV17023","article-title":"Pathophysiology of diabetic dyslipidemia","volume":"25","author":"Hirano","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_11","unstructured":"Dobi\u00e1sov\u00e1, M. (2004). Atherogenic Index of Plasma [Log (Triglycerides\/HDL-Cholesterol)]: Theoretical and Practical Implications, Oxford University Press."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0009-9120(01)00263-6","article-title":"The plasma parameter log (TG\/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL)","volume":"34","author":"Frohlich","year":"2001","journal-title":"Clin. Biochem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","article-title":"Use of metabolic markers to identify overweight individuals who are insulin resistant","volume":"139","author":"McLaughlin","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2337\/dc10-2234","article-title":"The triglyceride-to-HDL cholesterol ratio: Association with insulin resistance in obese youths of different ethnic backgrounds","volume":"34","author":"Giannini","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Baneu, P., V\u0103c\u0103rescu, C., Dr\u0103gan, S.-R., Cirin, L., Laz\u0103r-H\u00f6cher, A.-I., Cozgarea, A., Faur-Grigori, A.-A., Cri\u0219an, S., Gai\u021b\u0103, D., and Luca, C.-T. (2024). The triglyceride\/HDL ratio as a surrogate biomarker for insulin resistance. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071493"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MED.0000000000000241","article-title":"Triglycerides to high-density lipoprotein\u2013cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes","volume":"23","author":"Quispe","year":"2016","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.numecd.2021.11.005","article-title":"Triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular events in the general population: A systematic review and meta-analysis of cohort studies","volume":"32","author":"Chen","year":"2022","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1172\/JCI10762","article-title":"Insulin resistance and cardiovascular disease","volume":"106","author":"Ginsberg","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinte.165.12.1395","article-title":"Fasting triglyceride and the triglyceride\u2013HDL cholesterol ratio are not markers of insulin resistance in African Americans","volume":"165","author":"Sumner","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.metabol.2011.09.009","article-title":"The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort","volume":"61","author":"Gasevic","year":"2012","journal-title":"Metabolism"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/1479164113479809","article-title":"Comparison of the abilities of the plasma triglyceride\/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance","volume":"10","author":"Salazar","year":"2013","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026). Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes\u20142026. Diabetes Care, 49, S124\u2013S149.","DOI":"10.2337\/dc26-S006"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5455\/medarh.2019.73.163-168","article-title":"The triglyceride\/HDL ratio and triglyceride glucose index as predictors of glycemic control in patients with diabetes mellitus type 2","volume":"73","author":"Babic","year":"2019","journal-title":"Med. Arch."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4274\/meandros.galenos.2021.27132","article-title":"The Role of Triglyceride-HDL Ratio and Triglyceride-glucose Index in Estimating Glycemic Control in Patients with Type 2 Diabetes Mellitus","volume":"23","author":"Altun","year":"2023","journal-title":"Meandros Med. Dent. J."},{"key":"ref_25","first-page":"1255","article-title":"Association of triglyceride glucose index and triglyceride HDL ratio with glucose levels, microvascular and macrovascular complications in Diabetes Mellitus Type-2","volume":"39","author":"Jabeen","year":"2023","journal-title":"Pak. J. Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/VHRM.S209830","article-title":"High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus","volume":"15","author":"Artha","year":"2019","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1210\/jc.2018-01656","article-title":"Association between triglyceride level and glycemic control among insulin-treated patients with type 2 diabetes","volume":"104","author":"Zheng","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e47360","DOI":"10.1097\/MD.0000000000047360","article-title":"Are lipid-lowering therapies used according to the guidelines?: A real-world retrospective study of 1001 patients with type 2 diabetes","volume":"105","author":"Erol","year":"2026","journal-title":"Medicine"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., G\u00f8tzsche, P.C., and Vandenbroucke, J.P. (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040296"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","article-title":"A caution regarding rules of thumb for variance inflation factors","volume":"41","year":"2007","journal-title":"Qual. Quant."},{"key":"ref_32","first-page":"1","article-title":"Nitric Oxide Signaling in Inflammation and Oxidative Stress: Mechanistic Insights and Therapeutic Opportunities","volume":"1","author":"Yaghoubi","year":"2026","journal-title":"Nexus Pathophysiol. Ther. (NPT)"},{"key":"ref_33","first-page":"1","article-title":"Targeting Inflammatory Pathways: Are We Entering a New Era of Mechanism-Driven Therapeutics?","volume":"1","author":"Kordkatouli","year":"2026","journal-title":"Nexus Pathophysiol. Ther. (NPT)"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/9\/1995\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:27:38Z","timestamp":1788539258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/9\/1995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["biomedicines14091995"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines14091995","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}